tiprankstipranks
Trending News
More News >
Mustang Bio (MBIO)
:MBIO
Advertisement

Mustang Bio (MBIO) AI Stock Analysis

Compare
1,602 Followers

Top Page

MBIO

Mustang Bio

(NASDAQ:MBIO)

Rating:31Underperform
Price Target:
Mustang Bio's overall stock performance is hindered by significant financial instability, including zero revenues and continuous losses. While technical indicators suggest bearish momentum, the recent asset sale to AbbVie provides a glimmer of hope for cost reduction. However, the lack of earnings call data limits insights into future guidance, further emphasizing the need for caution.

Mustang Bio (MBIO) vs. SPDR S&P 500 ETF (SPY)

Mustang Bio Business Overview & Revenue Model

Company DescriptionMustang Bio, Inc. (MBIO) is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for the treatment of cancer and rare genetic diseases. The company's primary focus lies in advancing its gene and cell therapy platforms, which are designed to harness the power of the patient's immune system to target and eliminate diseased cells. Mustang Bio is involved in both clinical and preclinical development stages, working on a pipeline of promising therapeutic candidates.
How the Company Makes MoneyMustang Bio generates revenue primarily through strategic partnerships, licensing agreements, and collaborations with other biopharmaceutical companies and research institutions. These partnerships may involve upfront payments, milestone payments, and royalties based on the successful development and commercialization of their therapies. Additionally, Mustang Bio may also receive funding from grants or government contracts aimed at supporting innovative research and development in the field of gene and cell therapies. The company is focused on advancing its clinical trials to bring its products to market, which will eventually result in direct sales revenue from approved therapies.

Mustang Bio Financial Statement Overview

Summary
Mustang Bio faces significant financial challenges, including zero revenue, heavy losses, negative equity, and reliance on external financing. These factors highlight precarious financial health and the need for strategic initiatives to stabilize operations.
Income Statement
20
Very Negative
Mustang Bio has consistently reported zero revenue over the years, indicating no income generation from operations. The company's EBIT and net income are both negative, reflecting significant operational losses. The lack of revenue growth and continuous losses highlight potential challenges in achieving profitability.
Balance Sheet
15
Very Negative
The company's balance sheet reveals a negative stockholders' equity in the latest period, signaling financial instability. The debt-to-equity ratio cannot be calculated accurately due to negative equity. These factors point to high financial leverage and potential risks associated with insolvency.
Cash Flow
25
Negative
Mustang Bio's cash flows indicate negative operating cash flow and free cash flow, reflecting cash outflows from operations without revenue support. The company's reliance on financing activities to sustain operations poses a risk to long-term liquidity if external funding is not maintained.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue0.000.000.000.000.00
Gross Profit0.00-2.23M-3.03M-2.31M-1.78M
EBITDA-16.25M-48.06M-71.14M-64.05M-54.31M
Net Income-15.75M-51.60M-78.89M-64.08M-62.15M
Balance Sheet
Total Assets9.31M17.74M92.42M125.17M109.90M
Cash, Cash Equivalents and Short-Term Investments6.84M6.23M75.66M109.62M97.80M
Total Debt878.00K2.50M31.38M2.03M2.23M
Total Liabilities13.18M17.62M46.15M12.77M11.46M
Stockholders Equity-3.87M123.00K46.27M112.40M98.44M
Cash Flow
Free Cash Flow-11.41M-49.59M-68.14M-59.03M-41.73M
Operating Cash Flow-11.41M-49.48M-65.07M-53.67M-37.32M
Investing Cash Flow0.005.89M-2.95M-5.37M-4.41M
Financing Cash Flow11.27M-26.08M34.06M70.85M78.12M

Mustang Bio Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1.91
Price Trends
50DMA
1.57
Positive
100DMA
1.45
Positive
200DMA
5.03
Negative
Market Momentum
MACD
0.16
Positive
RSI
49.43
Neutral
STOCH
6.63
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MBIO, the sentiment is Negative. The current price of 1.91 is below the 20-day moving average (MA) of 2.13, above the 50-day MA of 1.57, and below the 200-day MA of 5.03, indicating a neutral trend. The MACD of 0.16 indicates Positive momentum. The RSI at 49.43 is Neutral, neither overbought nor oversold. The STOCH value of 6.63 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MBIO.

Mustang Bio Risk Analysis

Mustang Bio disclosed 65 risk factors in its most recent earnings report. Mustang Bio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Mustang Bio Peers Comparison

Overall Rating
UnderperformOutperform
Sector (55)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
55
Neutral
€4.81B17.05-48.29%2.18%15.31%-8.27%
31
Underperform
$8.36M270.52%85.97%
28
Underperform
$11.67M-120.01%97.84%
24
Underperform
$8.93M<0.0113.29%-261.69%
15
Underperform
$4.46M-206.26%75.68%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
MBIO
Mustang Bio
1.90
-15.34
-88.98%
WINT
Windtree Therapeutics
0.92
-283.08
-99.68%
AEON
AEON Biopharma
0.79
-139.61
-99.44%
DRMA
Dermata Therapeutics
0.70
-1.07
-60.45%

Mustang Bio Corporate Events

M&A TransactionsBusiness Operations and Strategy
Mustang Bio Sells Assets to AbbVie, Transfers Lease
Positive
Feb 13, 2025

Mustang Bio has entered into a Bill of Sale and Surrender Agreement with AbbVie Bioresearch Center Inc., effective from January 31, 2025. As part of this agreement, Mustang Bio will sell certain furniture, fixtures, and equipment located at their Worcester premises to AbbVie for $1.0 million, and AbbVie will take over the lease of the premises. This transaction is expected to potentially save Mustang Bio approximately $2.0 million in lease-related expenses.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 24, 2025